Natriuretic effect of an adenosine-1 receptor antagonist in cirrhotic patients with ascites

Gastroenterology. 1998 Aug;115(2):406-11. doi: 10.1016/s0016-5085(98)70207-0.

Abstract

Background & aims: The sodium and water retention and renal vasoconstriction exhibited by patients with cirrhotic ascites are similar to the changes observed by stimulation of renal adenosine 1 receptors. The aim of this study was to investigate the effects of FK352 (an adenosine 1 antagonist) on renal and systemic hemodynamics and renal function in cirrhotic patients with ascites.

Methods: p-Aminohippuric acid and inulin clearance, urine flow rate, sodium and potassium excretion, and free water clearance were measured for 2 hours before and after FK352 administration. Cardiac output, systemic vascular resistance, plasma angiotensin II level, plasma renin activity, and noradrenaline, adrenaline, and adenosine 3', 5'-cyclic monophosphate (cAMP) levels were also measured before and after FK352.

Results: Urine sodium excretion and urine flow rate increased after FK352 by a mean of 199.9% +/- 43.0% (P < 0.001) and 51.2% +/- 17.5% (P < 0.02), respectively. Plasma cAMP and angiotensin II levels and plasma renin activity also increased by 10. 8% +/- 3.2% (P < 0.01), 36.9% +/- 11.3% (P < 0.01), and 247.9% +/- 82.6% (P < 0.02), respectively. No change was detected in any other parameter.

Conclusions: The isokaliuretic improvement in natriuresis and diuresis suggests a role for adenosine 1 antagonism in the treatment of the renal abnormalities found in advanced cirrhosis.

MeSH terms

  • Ascites / etiology*
  • Female
  • Hemodynamics / drug effects
  • Hemodynamics / physiology
  • Hormones / blood
  • Humans
  • Kidney / drug effects
  • Kidney / physiopathology
  • Liver Cirrhosis / blood
  • Liver Cirrhosis / complications*
  • Liver Cirrhosis / physiopathology*
  • Male
  • Middle Aged
  • Natriuresis / drug effects*
  • Purinergic P1 Receptor Antagonists*
  • Pyrazoles / pharmacology*
  • Pyridines / pharmacology*

Substances

  • FK 352
  • Hormones
  • Purinergic P1 Receptor Antagonists
  • Pyrazoles
  • Pyridines